REG - Cambridge Cognition - Changes to Board and Management

Cambridge Cognition HoldingsAnnouncement

Yesterday 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250828:nRSb9508Wa&default-theme=true

RNS Number : 9508W  Cambridge Cognition Holdings PLC  28 August 2025

 

28 August 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Changes to Board and Management

Updates to leadership and Non-Executive governance

 

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group
specialising in digital health products that advance brain health research and
treatment, announces the following changes to the board in leadership and
Non-Executive governance.

Since the beginning of 2024 we have sought to grow and transition the Board
for the next stage of its development.  As part of this process, three new
independent Non-Executive Directors joined the Board - Stuart Gall, Nick
Rodgers, and Jon Kempster.  At the end of Q3 2024, changes were made to the
executive leadership.  Since that point we have monitored the performance of
the executive team and considered board structure for the next phase of the
Company's development.  Following this considered approach, we announce the
following updates.

Effective immediately, Rob Baker is appointed to the Board and as Senior
Executive Director.  Rob joined the Company in 2022 and will continue to
serve as Group Chief Operating Officer.

It is proposed that Alex Livingstone-Learmonth will join the Board subject to
completion of due diligence checks by the Company's Nominated Adviser.  Alex
joined the Company in early 2024 and has been instrumental in restoring growth
in the company's commercial activity, contributing to a more than doubling of
New Sales Orders in the first half of 2025.  He will continue in his role as
Chief Commercial Officer.

It is also proposed that Ronald Openshaw will join the Board subject to
completion of due diligence checks by the Company's Nominated Adviser.
 Ronald has served as a consultant to the business advising on strategic
matters since 2022 and in August 2024 took over interim leadership of the
Company's finance function.  Ronald will assume the role of Chief Financial
Officer and Head of Corporate Development with immediate effect.

A further announcement regarding the appointments of Alex and Ronald,
including the disclosures required under the AIM Rules for Companies, will be
made once the due diligence checks are complete.

Biographies for each of the above are set out below.

As part of our commitment to ongoing corporate governance, and following the
appointment of new Non-Executive Directors in 2024 and 2025, both Debra Leeves
and Richard Bungay will stand down from the Board on 31 December 2025. Debra
and Richard have served as Non-Executive Directors since 2019 and 2020
respectively.

Finally, Dr Steven Powell, Chair, who has previously served the Company as an
Executive Director since 2015 and as Non-Executive Chair since 2019, has
confirmed that he will not stand for re-election at the 2026 AGM. Having
completed a decade of service, Dr Steven Powell will stand down from the Board
at that point. Further announcements about the position of Chair will be made
ahead of that date.

Dr Steven Powell, Chair, said:

"The board has considered the leadership of the Company carefully since the
changes made in September last year. This has included assessing internal
candidates against external profiles.  Rob and Alex have guided the Company
through this period of change, and we have seen a sustained and meaningful
improvement in Company performance in terms of sales and operational
achievement.  Ronald's appointment completes the necessary changes to the
executive leadership and will enhance the executive team, not only in the
finance function but also in corporate development.

The enlarged non-executive team has worked intensively to support the change
in the Company's momentum. I am grateful for all of Debra and Richard's
support during challenging times, but it is now appropriate that we transition
Board membership for the next era in Cambridge Cognition's development.

We are delighted to announce these changes to our leadership as we all share
the same vision and commitment to deploy our technology to deliver shareholder
value and improve patients' lives."

 

Leadership Biographies

Rob Baker, Group Chief Operating Officer & Senior Executive Director, was
previously the Chief of Product and Operations at the Company. He joined the
Company as Head of Product in November 2022. Prior to this, Rob held several
senior roles at Amazon, including leading large operational teams to scale
Alexa voice technology improvements and led privacy and security operations.
In addition to his operational expertise, Rob Baker has significant sales and
marketing experience having been responsible for regional Amazon Echo device
sales, device expansion and large-scale e-commerce programs. Rob Baker began
his career at Siemens where he led contract delivery within the Mobility
Division before transitioning into regional management roles within the Smart
Infrastructure Division.

Alex Livingstone-Learmonth, Chief Commercial Officer, joined the Company in
February 2024 having previously worked in the clinical trial technology,
services and solutions industry for over 20 years. He previously held the role
of Vice President, Global Lead, Strategic Accounts at Calyx and Vice
President; Global Strategic Accounts, Business Development at Signant Health
(formerly CRF Health). Prior to this, Alex Livingstone-Learmonth gained 20
years of eClinical experience leading and building high-achieving global
commercial teams.

Ronald Openshaw, Chief Financial Officer & Head of Corporate Development,
has advised companies in the life science and healthcare sector on strategy,
operational delivery and acquisitions and disposals. He has served as Chief
Executive Officer and/or Chief Financial Officer of several companies
including Simbec-Orion, a clinical research organisation, Plethora Solutions,
a speciality pharmaceutical company and Pharmagene/Asterand - a pioneer in the
use of human tissue in drug discovery and development. Prior to these roles he
was a senior healthcare investment banker with both Jefferies and Panmure
Gordon. He is a Chartered Accountant having qualified at KPMG.

 

FURTHER INFORMATION:

The following additional information is provided in accordance with Rule 17
and Schedule Two Paragraph (g) of the AIM Rules for Companies:

 

Robert Roland Baker, aged 38, holds or has held the following directorships in
the last five years:

 Current directorships   Past directorships within the last five years
 None                    None

Save for the information disclosed above, there is no other information in
relation to Mr Baker that is required to be disclosed pursuant to Rule 17 and
Schedule Two paragraph (g) of the AІM Rules for Companies.

 

Enquiries:

 

 Cambridge Cognition Holdings plc                    Tel: 012 2381 0700 

 Rob Baker, Senior Executive Director                press@camcog.com (mailto:press@camcog.com)  

 and Group Chief Operating Officer

 Panmure Liberum Limited (NOMAD and Joint Broker)    Tel: 020 7886 2968

 Will Goode / Freddy Crossley / Mark Rogers          (Corporate Finance)

 Rupert Dearden                                      (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)              Tel: 020 3903 7715 

 David Poutney / Amber Higgs                          

 Hudson Sandler (Financial PR and IR)                Tel: 020 7796 4133 

 Dan de Belder / Hattie Dreyfus / Jackson Redley     cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

                            

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a brain health software group specialising in digital
health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a
strong global brand with scalable technology that will support the rising
world demand for diagnosing and treating brain health. The Company creates
shareholder value through organic sales growth, strategic partnerships, joint
ventures, and spinouts.  The Company has identified four market sectors:

·      Clinical Studies for new pharmaceuticals;

·      Academic Research for scientists to understand CNS disorders;

·     Healthcare to provide physicians with cognitive assessments to
allow them to diagnose and treat patients; and,

·     Consumer Health & Wellness to provide individuals access to
accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

END

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPRMLTMTITBTA